231 related articles for article (PubMed ID: 7585154)
1. Serum p53 antibodies as early markers of lung cancer.
Lubin R; Zalcman G; Bouchet L; Trédanel J; Legros Y; Cazals D; Hirsch A; Soussi T
Nat Med; 1995 Jul; 1(7):701-2. PubMed ID: 7585154
[TBL] [Abstract][Full Text] [Related]
2. Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma.
Iizasa T; Fujisawa T; Saitoh Y; Hiroshima K; Ohwada H
Cancer Immunol Immunother; 1998 Aug; 46(6):345-9. PubMed ID: 9756419
[TBL] [Abstract][Full Text] [Related]
3. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
[TBL] [Abstract][Full Text] [Related]
4. Implications of p53 alterations and anti-p53 antibody response in head and neck squamous cell carcinomas.
Lavieille JP; Righini C; Reyt E; Brambilla C; Riva C
Oral Oncol; 1998 Mar; 34(2):84-92. PubMed ID: 9682769
[TBL] [Abstract][Full Text] [Related]
5. Measurement and evaluation of serum anti-p53 antibody levels in patients with lung cancer at its initial presentation: a prospective study.
Segawa Y; Kageyama M; Suzuki S; Jinno K; Takigawa N; Fujimoto N; Hotta K; Eguchi K
Br J Cancer; 1998 Sep; 78(5):667-72. PubMed ID: 9744508
[TBL] [Abstract][Full Text] [Related]
6. Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer.
Tomkiel JE; Alansari H; Tang N; Virgin JB; Yang X; VandeVord P; Karvonen RL; Granda JL; Kraut MJ; Ensley JF; Fernández-Madrid F
Clin Cancer Res; 2002 Mar; 8(3):752-8. PubMed ID: 11895905
[TBL] [Abstract][Full Text] [Related]
7. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
8. Serum anti-p53 antibodies in lung cancer: comparison with established tumor markers.
Cioffi M; Vietri MT; Gazzerro P; Magnetta R; D'Auria A; Durante A; Nola E; Puca GA; Molinari AM
Lung Cancer; 2001; 33(2-3):163-9. PubMed ID: 11551411
[TBL] [Abstract][Full Text] [Related]
9. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
[TBL] [Abstract][Full Text] [Related]
10. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations.
Ralhan R; Nath N; Agarwal S; Mathur M; Wasylyk B; Shukla NK
Clin Cancer Res; 1998 Sep; 4(9):2147-52. PubMed ID: 9748133
[TBL] [Abstract][Full Text] [Related]
11. Serum anti-p53 autoantibodies in pleural malignant mesothelioma, lung cancer and non-neoplastic lung diseases.
Neri M; Betta P; Marroni P; Filiberti R; Cafferata M; Mereu C; Ivaldi G; Montanaro F; Puntoni R; Paganuzzi M
Lung Cancer; 2003 Feb; 39(2):165-72. PubMed ID: 12581569
[TBL] [Abstract][Full Text] [Related]
12. p53 antibodies in patients with various types of cancer: assay, identification, and characterization.
Lubin R; Schlichtholz B; Teillaud JL; Garay E; Bussel A; Wild CP
Clin Cancer Res; 1995 Dec; 1(12):1463-9. PubMed ID: 9815945
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment.
Zalcman G; Schlichtholz B; Trédaniel J; Urban T; Lubin R; Dubois I; Milleron B; Hirsch A; Soussi T
Clin Cancer Res; 1998 Jun; 4(6):1359-66. PubMed ID: 9626451
[TBL] [Abstract][Full Text] [Related]
14. Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies.
Moch C; Moysan A; Lubin R; de la Salmonière P; Soufir N; Galisson F; Vilmer C; Venutolo E; Le Pelletier F; Janin A; Basset-Séguin N
Br J Cancer; 2001 Dec; 85(12):1883-6. PubMed ID: 11747330
[TBL] [Abstract][Full Text] [Related]
15. Serum p53 antibodies in patients with oral lesions: correlation with p53/HSP70 complexes.
Kaur J; Srivastava A; Ralhan R
Int J Cancer; 1997 Dec; 74(6):609-13. PubMed ID: 9421357
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
Li P; Shi JX; Xing MT; Dai LP; Li JT; Zhang JY
Tumour Biol; 2017 Oct; 39(10):1010428317711662. PubMed ID: 29022480
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of serum p53 antibodies in lung cancer.
Mattioni M; Soddu S; Prodosmo A; Visca P; Conti S; Alessandrini G; Facciolo F; Strigari L
BMC Cancer; 2015 Mar; 15():148. PubMed ID: 25884692
[TBL] [Abstract][Full Text] [Related]
18. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue.
Wild CP; Ridanpää M; Anttila S; Lubin R; Soussi T; Husgafvel-Pursiainen K; Vainio H
Int J Cancer; 1995 Jun; 64(3):176-81. PubMed ID: 7622306
[TBL] [Abstract][Full Text] [Related]
19. Anti-p53 and anti-heat shock proteins antibodies in patients with malignant or pre-malignant lesions of the oral cavity.
Castelli M; Cianfriglia F; Manieri A; Palma L; Pezzuto RW; Falasca G; Delpino A
Anticancer Res; 2001; 21(1B):753-8. PubMed ID: 11299839
[TBL] [Abstract][Full Text] [Related]
20. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]